当前位置: X-MOL 学术Pediatr. Allergy Immunol. Pulmonol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Subcutaneous Immunoglobulin Twenty Percent Every Two Weeks in Pediatric Patients with Primary Immunodeficiencies: Subcohort Analysis of the IBIS Study.
Pediatric Allergy, Immunology, and Pulmonology ( IF 0.9 ) Pub Date : 2019-06-17 , DOI: 10.1089/ped.2018.0967
Clementina Canessa 1 , Vera Gallo 2 , Claudio Pignata 2 , Antonino Trizzino 3 , Simona Graziani 4 , Baldassarre Martire 5 , Viviana Moschese 4 , Valentina Palladino 6 , Giorgio Maria Boggia 7 , Andrea Matucci 8 , Antonio Pecoraro 9 , Giuseppe Spadaro 9 , Alessandra Vultaggio 8 , Chiara Azzari 1
Affiliation  

Background: Subcutaneous immunoglobulin G (SCIG) may be a better option than intravenous immunoglobulin G (IVIG) for patients with primary immunodeficiencies (PID) due to reduced systemic and serious adverse reactions and easier administration. The Infusione Bimensile di Immunoglobuline Sottocute (IBIS) study investigated the effects of Hizentra®, a 20%-concentrated SCIG, administered biweekly in patients with PID. This subanalysis aimed to evaluate clinical and laboratory outcomes in the IBIS pediatric subcohort. Methods: Thirteen children with PID were observed for 12 months retrospectively (with previous IVIG/SCIG) and prospectively with biweekly Hizentra. Results: Mean ± standard deviation serum IG levels during the retrospective (833.8 ± 175.7 mg/dL) and the prospective (842.0 ± 188.0 mg/dL) phases were comparable; there were also no differences in the number of infections. Conclusions: Biweekly Hizentra is a noninferior option with respect to previous IVIG/SCIG-based treatment.

中文翻译:

患有原发性免疫缺陷病的小儿患者,每两周皮下注射免疫球蛋白百分之二十:IBIS研究的亚队列分析。

背景:对于原发性免疫缺陷(PID)的患者,皮下免疫球蛋白G(SCIG)可能比静脉免疫球蛋白G(IVIG)更好,因为其减少了全身性和严重的不良反应,并且易于管理。Immunoglobuline Sottocute双向输注(IBIS)研究调查了Hizentra®(一种浓度为20%的SCIG)每两周一次对PID患者的影响。本子分析旨在评估IBIS小儿亚组的临床和实验室结果。方法:回顾性观察13例PID患儿(与先前的IVIG / SCIG对照)和前两次双周Hizentra随访12个月。结果:回顾性(833.8±175.7 mg / dL)阶段和预期(842.0±188.0 mg / dL)阶段的平均IG血清水平具有可比性;感染数量也没有差异。结论:相对于以前的基于IVIG / SCIG的治疗,双周Hizentra是一个不逊色的选择。
更新日期:2019-11-01
down
wechat
bug